NEW YORK (GenomeWeb News) – German biotech firm Protagen said today that it has sold its subsidiary Protagen Protein Services to venture capital fund Zukunftsfond Heilbronn.

The sale will provide Protagen with funds to support its diagnostic development efforts, the company said. Financial and other terms of the deal were not disclosed.

Spun out as a 100 percent subsidiary of Protagen in January 2012, Protagen Protein Services offers a variety of protein analysis services aimed at academic labs as well as biopharmaceutical and biosimilars work.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Chan Zuckerberg Initiative is investing in Cold Spring Harbor Laboratory's BioRxiv.

A study appearing in PLOS One finds that shortened consent forms don't affect clinical trial participants' understanding of the study.

The National Security Agency monitored signal intelligence for signs of "nefarious" genetic engineering projects, Gizmodo reports.

In Nature this week: barley genome sequenced, method for genotyping and phasing short tandem repeats, and more.